<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Regulation of blood <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations requires an adequate number of beta-cells that respond appropriately to blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels </plain></SENT>
<SENT sid="1" pm="."><plain>beta-Cell mass cannot yet be measured in humans in vivo, necessitating autopsy studies, although both pre- and postmorbid changes may confound this approach </plain></SENT>
<SENT sid="2" pm="."><plain>Autopsy studies report deficits in beta-cell mass ranging from 0 to 65% in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (T2DM), and approximately 70-100% in type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> (T1DM), and, when evaluated, increased beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in both T1DM and T2DM </plain></SENT>
<SENT sid="3" pm="."><plain>A deficit of beta-cell mass of approximately 50% in animal studies leads to <z:e sem="disease" ids="C0948379" disease_type="Disease or Syndrome" abbrv="">impaired insulin secretion</z:e> (when evaluated directly in the portal vein) and induction of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>We postulate three phases for <z:mp ids='MP_0002055'>diabetes</z:mp> progression </plain></SENT>
<SENT sid="5" pm="."><plain>Phase 1: selective beta-cell cytotoxicity (autoimmune in T1DM, unknown in T2DM) leading to impaired beta-cell function and gradual loss of beta-cell mass through <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>Phase 2: decompensation of <z:chebi fb="105" ids="17234">glucose</z:chebi> control when the pattern of portal vein insulin secretion is sufficiently impaired to cause hepatic <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Phase 3: adverse consequences of <z:chebi fb="105" ids="17234">glucose</z:chebi> toxicity accelerate <z:hpo ids='HP_0006279'>beta-cell dysfunction</z:hpo> and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The relative contribution of beta-cell loss versus <z:hpo ids='HP_0006279'>beta-cell dysfunction</z:hpo> to <z:mp ids='MP_0002055'>diabetes</z:mp> <z:hpo ids='HP_0003674'>onset</z:hpo> remains an area of controversy </plain></SENT>
<SENT sid="9" pm="."><plain>However, because cytotoxicity sufficient to induce beta-cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> predictably disturbs beta-cell function, it is naive to attempt to distinguish the relative contributions of these linked processes to <z:mp ids='MP_0002055'>diabetes</z:mp> <z:hpo ids='HP_0003674'>onset</z:hpo> </plain></SENT>
</text></document>